Conference Coverage
ReachMD brings you the latest research, announcements, and conversations from the most important medical conferences around the world. Join us on the conference floor with keynote speakers, experts, and opinion leaders.
1-15 of 495
Applying Real-World Data from SABCS 2025 to HR+ HER2- Breast Cancer Care
Project Oncology®Applying Real-World Data from SABCS 2025 to HR+ HER2- Breast Cancer Care
When Alopecia Areata Signals More than Hair Loss
DermConsultWhen Alopecia Areata Signals More than Hair Loss
Light-Based Therapies for Alopecia: What’s Established and What’s Emerging
DermConsultLight-Based Therapies for Alopecia: What’s Established and What’s Emerging
Advancing HER2-Targeted Therapy in GI Cancers
Project Oncology®Advancing HER2-Targeted Therapy in GI Cancers
How AI Is Transforming Biomarker Development in GI Oncology
Project Oncology®How AI Is Transforming Biomarker Development in GI Oncology
Surgical Insights on Gastroesophageal Cancer: Balancing Surveillance and Intervention
Project Oncology®Surgical Insights on Gastroesophageal Cancer: Balancing Surveillance and Intervention
- advertisement
The Next Chapter: SABCS 2025 and the Future of HR+ HER2− Breast Cancer Care
Project Oncology®The Next Chapter: SABCS 2025 and the Future of HR+ HER2− Breast Cancer Care
Genomic Profile of ER+ HER2- Metastatic Invasive Lobular Carcinoma
Project Oncology®Genomic Profile of ER+ HER2- Metastatic Invasive Lobular Carcinoma
Evaluating Post-CDK4/6 Therapy in PIK3CA-Mutated Metastatic Breast Cancer
Project Oncology®Evaluating Post-CDK4/6 Therapy in PIK3CA-Mutated Metastatic Breast Cancer
The Metabolic Roots of Early-Onset Colorectal Cancer
Project Oncology®The Metabolic Roots of Early-Onset Colorectal Cancer
AI-Assisted Colonoscopy Improves Polyp Detection and Diagnostic Accuracy
Project Oncology®AI-Assisted Colonoscopy Improves Polyp Detection and Diagnostic Accuracy
Evaluating PARP and ER Targeting in ER+/HER2– Breast Cancer
Project Oncology®Evaluating PARP and ER Targeting in ER+/HER2– Breast Cancer
- advertisement
From Resistance to Response: Evolving Treatment Pathways in HR+ Breast Cancer
Project Oncology®From Resistance to Response: Evolving Treatment Pathways in HR+ Breast Cancer
Tracking Lineage Infidelity in Pediatric B-ALL: New Insights From ASH
Project Oncology®Tracking Lineage Infidelity in Pediatric B-ALL: New Insights From ASH
Giredestrant and Everolimus in HR+/HER2- Breast Cancer: Insights from evERA
Project Oncology®Giredestrant and Everolimus in HR+/HER2- Breast Cancer: Insights from evERA
